Sign In
Buy ERAS
$18.53
-0.650 (-3.39%)
At Close: Jul 10, 2026
Financial Comparison: Erasca (NASDAQ:ERAS) vs. Oncolytics Biotech (NASDAQ:ONCY)
02:31am, Friday, 24'th Apr 2026
Oncolytics Biotech (NASDAQ: ONCY - Get Free Report) and Erasca (NASDAQ: ERAS - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on t
Erasca (NASDAQ:ERAS) Shares Gap Up – Here’s Why
04:27am, Wednesday, 15'th Apr 2026
Erasca, Inc. (NASDAQ: ERAS - Get Free Report) shares gapped up prior to trading on Monday. The stock had previously closed at $17.01, but opened at $17.84. Erasca shares last traded at $16.3150, with
Erasca, Inc. (NASDAQ:ERAS) Receives $16.63 Consensus Price Target from Brokerages
01:30am, Tuesday, 14'th Apr 2026
Shares of Erasca, Inc. (NASDAQ: ERAS - Get Free Report) have earned an average rating of "Moderate Buy" from the ten research firms that are currently covering the company, Marketbeat Ratings reports.
Erasca (NASDAQ:ERAS) Hits New 1-Year High – Should You Buy?
04:57am, Tuesday, 07'th Apr 2026
Erasca, Inc. (NASDAQ: ERAS - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $18.20 and last traded at $17.12, with a volume of 525045
JPMorgan Chase & Co. Has $2.77 Million Stock Holdings in Erasca, Inc. $ERAS
04:45am, Monday, 06'th Apr 2026
JPMorgan Chase and Co. trimmed its stake in shares of Erasca, Inc. (NASDAQ: ERAS) by 7.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and
Ebun Garner Sells 80,000 Shares of Erasca (NASDAQ:ERAS) Stock
04:50am, Sunday, 05'th Apr 2026
Erasca, Inc. (NASDAQ: ERAS - Get Free Report) insider Ebun Garner sold 80,000 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $16.40, for a
Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't
05:44pm, Thursday, 26'th Mar 2026
20,000 shares of Common Stock were exercised from options and sold on March 4, 2026, yielding a transaction value of ~$301,000 at a weighted average price of $15.04 per share. The activity represented
Erasca (NASDAQ:ERAS) Stock Price Up 10.3% Following Better-Than-Expected Earnings
02:56am, Friday, 20'th Mar 2026
Erasca, Inc. (NASDAQ: ERAS - Get Free Report)'s share price rose 10.3% on Thursday following a stronger than expected earnings report. The company traded as high as $14.94 and last traded at $14.89. A
Brokerages Set Erasca, Inc. (NASDAQ:ERAS) PT at $12.89
01:32am, Friday, 20'th Mar 2026
Shares of Erasca, Inc. (NASDAQ: ERAS - Get Free Report) have received an average recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat repo
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
04:01pm, Thursday, 12'th Mar 2026
Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
08:00am, Tuesday, 10'th Mar 2026
Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy ERAS-0015's promising early clinical data underscore its potential to be a best-in-class RAS-targeti
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
11:17am, Monday, 09'th Mar 2026
Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst.
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
07:01am, Thursday, 05'th Mar 2026
ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, Mar
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
08:00am, Tuesday, 24'th Feb 2026
The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase 1
Erasca Touts Early ERAS-0015 Responses, Potency Edge in Guggenheim Fireside Chat
04:44am, Sunday, 15'th Feb 2026
Erasca (NASDAQ: ERAS) executives highlighted early clinical signals and the company's strategy to differentiate its RAS-focused pipeline during a Guggenheim fireside chat featuring CEO Jonathan Lim an
